Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency

Inclusion Criteria: * Patients, male or females aged 18 to 75 years old * BMI≤40 * Presence of chronic venous insufficiency which is rated between functional classes CEAP 1-4 * Patients diagnosed with superficial vein thrombophlebitis and have skin reaction by redness, swelling, fever and pain symptoms.or patients presenting a painful venous symptomatology in the lower limbs for at least 30 days. * Willing and able to give written informed consent prior to participation in the trial * Patients expected to be compliant with the study treatment Exclusion Criteria: * Known allergy to the product's ingredients * Pregnancy or breastfeeding * Patient is involved in any other clinical trial * Deep vein thrombosis * Stasis dermatitis * The patient is taking non-steroids anti-inflammatory drugs include oral , topical creams or patch form) * Open ulcers or lower extremity amputation * Patient treated by venotonic treatments or vascular protectants or assimilated dietary supplements or homeopathic treatments or diuretics within 15 days prior inclusion * Patient presenting permanent oedema, * Patient with a history of lower limbs trauma responsible for sequel pains * NYHA III and IV Heart Failure * Renal Failure * Untreated or uncontrolled Arterial Hypertension * Hepatic Failure * History of a known liver disease such as hepatitis A, hepatitis B, or C. * Malignant neoplasms, from any etiology, or who are receiving any type of anticancer treatment, unless when properly treated and with no evidence of recurrence during the last five years * Previous history of alcoholism, drug abuse, psychological or emotional problems in the last 5 years that can invalidate the Informed Consent Form or restrain participant's ability to comply with the requirements of the protocol. * Immobility.